



Docket No.: VPI/02-129 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Mark Ledebøer, et al.  
SERIAL NUMBER: 10/657,811 EXAMINER: Not Yet Assigned  
FILING DATE: September 8, 2003 ART UNIT: 1614  
FOR: ISOXAZOLES AND USES THEREOF

March 16, 2004  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS:     Ledeboer, et al.  
U.S.S.N.:        10/657,811

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/02-121 US.

Respectfully submitted,



Karoline K. M. Shair, Reg. No. 44,332  
Attorney for Applicants  
c/o     Vertex Pharmaceuticals Incorporated  
          130 Waverly Street  
          Cambridge, Massachusetts 02139  
          Tel: (617) 444-6536  
          Fax: (617) 444-6483





Docket No.: VPI/02-121 US

**Certificate Of Mailing Under 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On March 16, 2004  
Date

1. Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (in duplicate); and
3. Cited References (B1 and C1);
4. This Return Postcard Receipt.

Karen DiRocco  
Signature

Karen DiRocco  
Typed or printed name of person signing Certificate